CAWM
VIR icon

Capital A Wealth Management’s Vir Biotechnology VIR Stock Holding History

Capital A Wealth Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-41
Closed -$266 – 821
2025
Q1 		$266 Hold
41
– – ﹤0.01% 669
2024
Q4 		$301 Buy
+41
New +$323 ﹤0.01% 703

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital A Wealth Management's VIR Position: Q2 2025 in Review

Capital A Wealth Management sold out of Vir Biotechnology (VIR) in Q2 2025, closing a stake of 41 shares — an estimated $266 sold.

Capital A Wealth Management first reported a position in VIR in Q4 2024 and held it in 2 quarters. The position peaked at $301 in Q4 2024. 213 funds tracked by Wall St. Rank hold VIR as of Q2 2025.

  • Capital A Wealth Management reported no remaining Vir Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Capital A Wealth Management sold 41 Vir Biotechnology shares in Q2 2025, an estimated $266.
  • Capital A Wealth Management first reported a position in Vir Biotechnology in Q4 2024 and held it in 2 quarters.
  • Capital A Wealth Management's Vir Biotechnology position peaked at $301 in Q4 2024.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2025.

Based on Capital A Wealth Management's 13F filing for Q2 2025, filed 26 Sep 2025.